iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Sees Significant Increase in Short Interest

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totaling 108,461 shares, a growth of 382.5% from the June 15th total of 22,477 shares. Approximately 1.9% of the shares of the company are short sold. Based on an average daily volume of 77,170 shares, the short-interest ratio is currently 1.4 days.

iShares Genomics Immunology and Healthcare ETF Trading Down 2.8%

Shares of NYSEARCA IDNA traded down $0.95 during midday trading on Friday, hitting $33.55. The company’s stock had a trading volume of 55,587 shares, compared to its average volume of 44,156. The firm has a market capitalization of $194.59 million, a price-to-earnings ratio of 14.76 and a beta of 0.92. The stock has a fifty day moving average price of $30.71 and a 200 day moving average price of $29.59. iShares Genomics Immunology and Healthcare ETF has a one year low of $20.93 and a one year high of $34.97.

Institutional Trading of iShares Genomics Immunology and Healthcare ETF

A hedge fund recently raised its position in iShares Genomics Immunology and Healthcare ETF stock. Ameriprise Financial Inc. boosted its position in shares of iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) by 8.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,473 shares of the company’s stock after acquiring an additional 5,540 shares during the period. Ameriprise Financial Inc. owned 1.42% of iShares Genomics Immunology and Healthcare ETF worth $1,688,000 as of its most recent SEC filing.

iShares Genomics Immunology and Healthcare ETF Company Profile

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.